Heres what data suggests: In a clinical trial , 2.4% of people taking semaglutide (the active ingredient in Wegovy) reported sleep disturbances
International Use: T1 is approved in some countries for specific conditions, but these approvals do not apply within the U.S
Think of it like this: Novo Nordisk developed semaglutide, got it approved for diabetes under the name Ozempic, then later reformulated it at a higher dose and got separate FDA approval for weight loss under the name Wegovy
The top reasons Ozempic users are going to the hospital and the Wild West factor that could be driving an unexpected issue See more of our coverage in your search results
doi: 10.5555/20203153822 Google Scholar Barsky, M., St Marie, P., Rahil, T., Markenson, G